<DOC>
	<DOCNO>NCT02223468</DOCNO>
	<brief_summary>The microbiota represent collection microbial community colonize host . In health , microbiota protects pathogens maturation immune system . In return , immune system determine composition microbiota . Altered microbial composition ( dysbiosis ) correlate number disease human . The real role microbiota transplant recipient still unknown even though suspect may affect directly indirectly immunosuppressive drug antimicrobial prophylaxis take transplant patient , well inflammatory process secondary ischemia/reperfusion injury . A number study investigate impact liver transplantation intestinal microbiota . In recent analysis stool flora ( Microb Ecol 2013 ; 65 : 781-791 ) 12 liver transplant recipient , change microbiota correlate post-transplant infection . The author suggest shift pathogenic strain bacteria due use prophylactic antibiotic may contribute post-transplant complication . In large study , Wu et al ( Hepatobiliary Pancreat Dis Int 2012 ; 11 : 40-50 ) demonstrate marked change gut microbiota post-transplantation increase Enterobacteriaceae Enterococcus , reduction Eubacteria , Bifidobacterium Lactobacillus specie . These change , however , resolve time 6 month , time bacterial prophylaxis end immunosuppression reduce . A good characterization impact post-transplant therapy human microbiota potential improve understanding infection process translate development new therapeutic strategy . The main goal study characterize intestinal microbiota confirm bacterial DNA peripheral blood portal lymph node patient affect end-stage chronic liver disease , analyze evolution moment inclusion wait list throughout first year liver transplantation . For patient , healthy CONTROL similar age ( Â± 10 year ) select family setting , one sample obtain enrollment phase . The second goal analyze potential association microbiota flora transplant outcome period .</brief_summary>
	<brief_title>Human Microbiota Liver Transplant</brief_title>
	<detailed_description />
	<criteria>First liver transplant Patients age 1870 year Able consent agree participate current study one year Multiorgan transplantation and/or liver transplant cardiac arrest donor and/or ABO incompatibility . Uncontrolled concomitant infection ( include HIV seropositivity ) and/or diarrhoea , vomit active gastric ulcer . Fulminant hepatic insufficiency first indication liver transplant Hemodynamic instability prior liver transplant . Recipient present present previous neoplasia , except nonmetastatic basal squamous cutaneous carcinoma localize hepatocarcinoma diameter &lt; 5cm &lt; 3known lesion diameter &lt; 3cm . Significant comorbidity Breastfeeding female patient fertile age without negative pregnancy test accepting use reliable fertility control method Any pretransplant antibiotherapy ( oral endovenous ) enrol clinical assay</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Intestinal Microbiota</keyword>
	<keyword>Liver Transplant</keyword>
	<keyword>Acute Rejection</keyword>
	<keyword>Infection</keyword>
</DOC>